Volume 15, Number 6—June 2009
Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria
Highlight and copy the desired format.
|EID||Christova I, Di Caro A, Papa A, Castilletti C, Andonova L, Kalvatchev N, et al. Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria. Emerg Infect Dis. 2009;15(6):983-985. https://dx.doi.org/10.3201/eid1506.081567|
|AMA||Christova I, Di Caro A, Papa A, et al. Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria. Emerging Infectious Diseases. 2009;15(6):983-985. doi:10.3201/eid1506.081567.|
|APA||Christova, I., Di Caro, A., Papa, A., Castilletti, C., Andonova, L., Kalvatchev, N....Superiore di Sanità, I. (2009). Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria. Emerging Infectious Diseases, 15(6), 983-985. https://dx.doi.org/10.3201/eid1506.081567.|
To the Editor: Crimean-Congo hemorrhagic fever virus (CCHFV) causes a severe multisystem disease characterized by profuse bleeding with a case-fatality rate as high as 30%. The infection is endemic to the Balkans (1,2). In Bulgaria, most cases are reported from the central and eastern parts of the country (3,4). We report a cluster of cases observed in early spring 2008 in southwestern Bulgaria, an area considered at low risk for CCHF outbreaks.
The index case-patient was a 49-year-old man in whom fever, severe myalgia and joint pain, diarrhea for 1 day, cough, and weakness developed on March 20. Three days before, while not using hand protection, he removed ticks from cows. On March 25, severe epistaxis developed and he was hospitalized. His condition rapidly deteriorated; leukopenia, thrombocytopenia, and elevated levels of liver enzymes developed, and he died on March 26. The autopsy found hemorrhages in the lungs but not in the hypophysis or gastrointestinal tract. Immunoglobulin (Ig) M antibodies against CCHFV were detected in the serum sample.
The second case-patient was a 34-year-old man who had removed ticks from cows from the same herd as the index case-patient. Symptoms developed on March 23 and he was hospitalized on March 26 with fever, diarrhea, and bloody sputum. Laboratory findings showed moderate leukopenia and thrombocytopenia. His condition improved within 1 week. IgM antibodies against CCHFV were detected in a serum sample collected during the acute phase of the disease.
The third confirmed case-patient was a 52-year-old woman (nurse) who cared for the index case-patient after his hospital admission. Although she reported wearing gloves, she was extensively exposed to the patient’s blood and vomit and received immunoprophylaxis (specific hyperimmune gamma globulins). On March 28, a mild disease characterized by fever, headache, weakness, and maculopapular rash with petechiae developed; she was hospitalized on April 2. She had leukopenia, thrombocytopenia, and normal levels of liver enzymes. The serum sample collected during the acute phase of the disease was IgM positive, and a 4-fold increase was present in the IgG titer in a sample collected during the convalescent phase (from 160 to 640). Blood and serum samples taken during the acute phase of the disease were positive for CCHFV by real-time PCR (5) and reverse transcription–nested PCR (6). Purified PCR product was sequenced; the nucleotide sequence was submitted to GenBank (accession no. FJ160262). Viral load was 3.88 × 107 copies/mL.
The fourth confirmed case-patient was a 50-year-old woman, the wife of the index case-patient. She was hospitalized April 10 with fever, headache, myalgia, weakness, stomach pain, and nausea. She reported exposure to her husband’s blood before hospital admission. Thus, hyperimmune gamma globulins against CCHFV were administered. She had leukopenia, thrombocytopenia, and elevated levels of aspartate aminotransferase and alanine aminotransferase. The symptoms lasted only 7 days. CCHFV was detected by both PCRs (5,6) in a serum sample taken on day 3 of the disease; sequence of the PCR products was submitted to GenBank (accession no. FJ445749).
A phylogenetic tree including sequences from the third and fourth cases was constructed (Figure). The 2 sequences clustered within the Europe/Turkey clade. The genetic distance between the 2 strains was 1.15%, but the 2 sequences were identical at the amino acid level. Sequences from the present study showed 96.4%–98.8% similarity with respective CCHFV sequences from Bulgaria from a former study (BUL10/02 and BUL1/03) (3) but differed from the Kosovo 9553/2001 strain by 0.8%–2.0% and from the Greek 66/08 strain by 1.2%–2.4%.
Two additional suspected CCHF cases occurred in the same area, on March 30 and April 9 (7). Both persons were negative for CCHFV infection. All 119 ticks of various species (Hyalomma marginatum, Dermacentor marginatus, Rhipicephalus bursa, Ixodes ricinus) collected from the area and tested by reverse transcription–nested PCR were negative for CCHFV.
This cluster of CCHF cases has several important highlights. First, it occurred in a region that was considered to have low CCHF endemicity; however, the area is only a few kilometers from Greece, where a human fatal case was observed in June 2008 (8). The index case was observed earlier in the year than in previous years, and clinical manifestations of the cases were unusual (absence of craniopharyngeal syndrome and bleeding from gastrointestinal tract that are typical for CCHF patients from Bulgaria); in the fatal case, autopsy of the patient showed hemorrhages only in the lungs. Two cases were attributable to tick exposure, whereas the other 2 were most likely secondary cases attributable to contact with the index case-patient (in this regard, CCHFV sequences of the secondary cases were almost identical). Finally, the longer incubation period of the wife of the index case-patient might be associated with administration of hyperimmune gamma globulin against CCHFV.
In conclusion, CCHF emerged in southwestern Bulgaria near the border with Greece. Person-to-person transmission emphasizes the need for rapid diagnosis of CCHF, especially in cases with atypical clinical manifestations.
We thank Licia Bordi, Eleonora Lalle, Silvia Meschi, and Roberta Chiappini for valuable help in tick investigations.
This work was partially funded by RiViGene (contract no. SSPE-CT-2005-022639).
- Ergonul O, Whitehouse CA. Crimean-Congo hemorrhagic fever, a global perspective. New York: Springer; 2007.
- Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006;6:203–14.
- Papa A, Christova I, Papadimitriou E, Antoniadis A. Crimean-Congo hemorrhagic fever in Bulgaria. Emerg Infect Dis. 2004;10:1465–7.
- Monev V, Dikov I, Kamarinchev B. Crimean-Congo-haemorrhagic fever. In: Serbezov V and Kalvatchev Z, editors. Arbovirus infections viral haemorrhagic fevers and biol-terrorism [in Bulgarian]. Sofia; 2005. p. 130–42.
- Papa A, Drosten C, Bino S, Papadimitriou E, Panning M, Velo E, Viral load in Crimean-Congo hemorrhagic fever. Emerg Infect Dis. 2007;13:805–6.
- Rodriguez LL, Maupin GO, Ksiazek TG, Rollin PE, Khan AS, Schwarz TF, Molecular investigation of a multisource outbreak of Crimean-Congo hemorrhagic fever in the United Arab Emirates. Am J Trop Med Hyg. 1997;57:512–8.
- Kunchev A, Kojouharova M. Probable cases of Crimean-Congo-haemorrhagic fever in Bulgaria: a preliminary report. Euro Surveill. 2008;13. pii: 18845.
- Papa A, Maltezou HC, Tsiodras S, Dalla VG, Papadimitriou T, Pierroutsakos I, A case of Crimean-Congo haemorrhagic fever in Greece, June 2008. Euro Surveill. 2008;13. pii: 18952.
- Figure. Phylogenetic tree of partial sequence (256 bp) of Crimean-Congo hemorrhagic fever (CCHF) virus nucleoprotein gene. CCHF virus sequences are listed as viral strain name and country of origin. Sequence of...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Iva Christova, National Center of Infectious and Parasitic Diseases, Blvd Yanko Sakazov 26, Sofia 1504, Bulgaria
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 08, 2010
- Page last updated: December 08, 2010
- Page last reviewed: December 08, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)